KRAS and cancer: Although oncogenic Kras mutation in mouse PDAC is critical for cancer initiation, constitutively activated mutant KRAS alone is insufficient for tumor onset; rather, it requires partner mutations such as the P53 tumor suppressor gene, as well as cytokines produced by different cell types within the tumor mass [38].